The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
Hiroyuki Suzuki,1 Seita Morishita,1 Ryohsuke Kohmoto,1 Masanori Fukumoto,1 Takaki Sato,1 Teruyo Kida,1 Mari Ueki,1 Hidehiro Oku,1 Kimitoshi Nakamura,2 Tsunehiko Ikeda1 1Department of Ophthalmology, Osaka Medical College, Takatsuki-City, Osaka, Japan; 2Nakamura Eye Clinic, Matsumoto-City, Nagano, Ja...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ec842e4caac94da99a3fd3f97431c6cb |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ec842e4caac94da99a3fd3f97431c6cb |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ec842e4caac94da99a3fd3f97431c6cb2021-12-02T00:52:18ZThe effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection1177-5483https://doaj.org/article/ec842e4caac94da99a3fd3f97431c6cb2017-08-01T00:00:00Zhttps://www.dovepress.com/the-effect-of-vitreomacular-adhesion-in-exudative-age-related-macular--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Hiroyuki Suzuki,1 Seita Morishita,1 Ryohsuke Kohmoto,1 Masanori Fukumoto,1 Takaki Sato,1 Teruyo Kida,1 Mari Ueki,1 Hidehiro Oku,1 Kimitoshi Nakamura,2 Tsunehiko Ikeda1 1Department of Ophthalmology, Osaka Medical College, Takatsuki-City, Osaka, Japan; 2Nakamura Eye Clinic, Matsumoto-City, Nagano, Japan Purpose: To investigate whether vitreomacular adhesion (VMA) affects the outcome of anti-vascular endothelial growth factor (VEGF) therapy for the treatment of exudative age-related macular degeneration (AMD) in Japanese patients. Subjects and methods: Of 88 Japanese AMD patients (28 men and 60 women, mean age: 72.7±7.5 years) who underwent intravitreal injection of ranibizumab for 3 years from 2010 to 2013, this study involved 12 eyes of 12 patients (10 men and two women) in whom VMA was observed based on optical coherence tomography (OCT) findings (VMA [+] group) and 17 eyes of 16 patients (seven men and nine women, control group) in whom no VMA was observed (VMA [-] group). In all enrolled patients, ranibizumab was administered monthly for 3 months, and then administered as needed (ie, pro re nata) when deterioration was observed. The two groups were then compared in regard to changes in visual acuity (VA) and the frequency of ranibizumab administration over a 1-year period. Results: No significant difference was found between the two groups in regard to the transformation of the mean logarithm of the minimum angle of resolution VA change after the first visit. Over the 1-year treatment, the mean frequency of ranibizumab administration for the VMA (+) group was 5.6±2.5 times and for the VMA (-) group was 3.8±1.1 times, thus illustrating a significant difference between the two groups (Mann–Whitney’s U-test: P<0.05). Conclusion: Our findings show that the mean frequency of ranibizumab administration for the VMA (+) group was higher than that in the VMA (-) group, thus indicating that VMA might possibly be involved in the progress of AMD pathology. Keywords: age-related macular degeneration, vitreomacular adhesion, anti-VEGF therapy, ranibizumab, optical coherence tomographySuzuki HMorishita SKohmoto RFukumoto MSato TKida TUeki MOku HNakamura KIkeda TDove Medical Pressarticleage-related macular degenerationvitreomacular adhesionanti-VEGF therapyranibizumaboptical coherence tomographyOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 1471-1475 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
age-related macular degeneration vitreomacular adhesion anti-VEGF therapy ranibizumab optical coherence tomography Ophthalmology RE1-994 |
| spellingShingle |
age-related macular degeneration vitreomacular adhesion anti-VEGF therapy ranibizumab optical coherence tomography Ophthalmology RE1-994 Suzuki H Morishita S Kohmoto R Fukumoto M Sato T Kida T Ueki M Oku H Nakamura K Ikeda T The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection |
| description |
Hiroyuki Suzuki,1 Seita Morishita,1 Ryohsuke Kohmoto,1 Masanori Fukumoto,1 Takaki Sato,1 Teruyo Kida,1 Mari Ueki,1 Hidehiro Oku,1 Kimitoshi Nakamura,2 Tsunehiko Ikeda1 1Department of Ophthalmology, Osaka Medical College, Takatsuki-City, Osaka, Japan; 2Nakamura Eye Clinic, Matsumoto-City, Nagano, Japan Purpose: To investigate whether vitreomacular adhesion (VMA) affects the outcome of anti-vascular endothelial growth factor (VEGF) therapy for the treatment of exudative age-related macular degeneration (AMD) in Japanese patients. Subjects and methods: Of 88 Japanese AMD patients (28 men and 60 women, mean age: 72.7±7.5 years) who underwent intravitreal injection of ranibizumab for 3 years from 2010 to 2013, this study involved 12 eyes of 12 patients (10 men and two women) in whom VMA was observed based on optical coherence tomography (OCT) findings (VMA [+] group) and 17 eyes of 16 patients (seven men and nine women, control group) in whom no VMA was observed (VMA [-] group). In all enrolled patients, ranibizumab was administered monthly for 3 months, and then administered as needed (ie, pro re nata) when deterioration was observed. The two groups were then compared in regard to changes in visual acuity (VA) and the frequency of ranibizumab administration over a 1-year period. Results: No significant difference was found between the two groups in regard to the transformation of the mean logarithm of the minimum angle of resolution VA change after the first visit. Over the 1-year treatment, the mean frequency of ranibizumab administration for the VMA (+) group was 5.6±2.5 times and for the VMA (-) group was 3.8±1.1 times, thus illustrating a significant difference between the two groups (Mann–Whitney’s U-test: P<0.05). Conclusion: Our findings show that the mean frequency of ranibizumab administration for the VMA (+) group was higher than that in the VMA (-) group, thus indicating that VMA might possibly be involved in the progress of AMD pathology. Keywords: age-related macular degeneration, vitreomacular adhesion, anti-VEGF therapy, ranibizumab, optical coherence tomography |
| format |
article |
| author |
Suzuki H Morishita S Kohmoto R Fukumoto M Sato T Kida T Ueki M Oku H Nakamura K Ikeda T |
| author_facet |
Suzuki H Morishita S Kohmoto R Fukumoto M Sato T Kida T Ueki M Oku H Nakamura K Ikeda T |
| author_sort |
Suzuki H |
| title |
The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection |
| title_short |
The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection |
| title_full |
The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection |
| title_fullStr |
The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection |
| title_full_unstemmed |
The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection |
| title_sort |
effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/ec842e4caac94da99a3fd3f97431c6cb |
| work_keys_str_mv |
AT suzukih theeffectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT morishitas theeffectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT kohmotor theeffectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT fukumotom theeffectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT satot theeffectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT kidat theeffectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT uekim theeffectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT okuh theeffectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT nakamurak theeffectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT ikedat theeffectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT suzukih effectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT morishitas effectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT kohmotor effectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT fukumotom effectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT satot effectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT kidat effectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT uekim effectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT okuh effectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT nakamurak effectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection AT ikedat effectofvitreomacularadhesioninexudativeagerelatedmaculardegenerationontheresultsofranibizumabintravitrealinjection |
| _version_ |
1718403470435811328 |